o NoneEntity Type
0001649989
Oncobiologics, Inc.
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Outlook Therapeutics, Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Outlook Therapeutics, Inc. 
Street Address 1Street Address 2
 7 CLARKE DRIVE 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 CRANBURY NEW JERSEY 08512 6096193990 



3. Related Persons
Last NameFirst NameMiddle Name
ThurmanRandy
Street Address 1Street Address 2
c/o Outlook Therapeutics, Inc.7 Clarke Drive
CityState/Province/CountryZIP/Postal Code
CRANBURYNEW JERSEY08512
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HaddadinYezan
Street Address 1Street Address 2
c/o Outlook Therapeutics, Inc.7 Clarke Drive
CityState/Province/CountryZIP/Postal Code
CRANBURYNEW JERSEY08512
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HilzingerKurtJ.
Street Address 1Street Address 2
c/o Outlook Therapeutics, Inc.7 Clarke Drive
CityState/Province/CountryZIP/Postal Code
CRANBURYNEW JERSEY08512
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
KenyonLawrenceA.
Street Address 1Street Address 2
c/o Outlook Therapeutics, Inc.7 Clarke Drive
CityState/Province/CountryZIP/Postal Code
CRANBURYNEW JERSEY08512
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
SukhtianFaisalG.
Street Address 1Street Address 2
c/o Outlook Therapeutics, Inc.7 Clarke Drive
CityState/Province/CountryZIP/Postal Code
CRANBURYNEW JERSEY08512
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
DagnonTerry
Street Address 1Street Address 2
c/o Outlook Therapeutics, Inc.7 Clarke Drive
CityState/Province/CountryZIP/Postal Code
CranburyNEW JERSEY08512
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
EvansonJeff
Street Address 1Street Address 2
c/o Outlook Therapeutics, Inc.7 Clarke Drive
CityState/Province/CountryZIP/Postal Code
CranburyNEW JERSEY08512
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance x Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-02-24 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 H.C. Wainwright & Co., LLC 375
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 430 Park Avenue  
City State/Province/CountryZIP/Postal Code
 NewYork NEW YORK 10022
State(s) of Solicitation o All States o Foreign/Non-US
 ILLINOIS
 NEW JERSEY
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 7971155 USD o Indefinite
Total Amount Sold $ 7971155 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 Includes amounts receivable upon the exercise of warrants; such warrants have not yet been exercised


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 7


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 540400 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
 In addition, the placement agent was reimbursed $135,000 for expenses relating to the offering and received $77,200 for management fees.


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Outlook Therapeutics Charts.
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Outlook Therapeutics Charts.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No OTLK Message Board. Create One! See More Posts on OTLK Message Board See More Message Board Posts

Outlook Therapeutics, Inc. News

Loading Messages....

More Outlook Therapeutics, Inc. News Articles